growth hormone secretagogue receptor ghsr clinical trial intelligence

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

MK-0677, an investigational drug developed by Merck Sharp & Dohme LLC, targets cognitive decline in Alzheimer's disease (AD), a significant market with a growing patient population. The Phase 2 trial, completed in January 2006, involved 512 participants and aimed to evaluate the drug's efficacy in slowing AD progression. Despite the potential market opportunity, the competitive landscape includes established therapies and emerging candidates, necessitating thorough diligence to assess MK-0677's unique value proposition and market entry strategy.

Matched by target_normalized: Growth hormone secretagogue receptor (GHSR)